Bliss GVS Pharma Ltd Financials
Company Logo

Bliss GVS Pharma Ltd Financial Statement

Bliss GVS Pharma Ltd Income Statement

Quarterly

Annual

*All values are in Rs. Cr

Particulars
Sep 2024
Revenue191.00
Operating Expense157.27
Net Profit17.04
Net Profit Margin8.92
Earning Per Share1.63
EBIDTA35.62
Effective Tax Rate25.91

Bliss GVS Pharma Ltd Profit & Loss

*All values are in Rs. Cr

Standalone

Consolidated

Particulars
Mar 2024
Total Revenue Annual605.46
Operating Expenses Annual498.29
Operating Profit Annual99.58
Interest Annual5.81
Depreciation23.52
Net Profit Annual50.64
Tax Annual19.61

Bliss GVS Pharma Ltd Cash Flow

*All values are in Rs. Cr

Standalone

Consolidated

Particulars
Mar 2024
Cash Flow at the Beginning18.60
Cash Flow from Operations125.92
Cash Flow from Investing-109.59
Cash Flow from Financing-20.76
Cash Flow at the End14.17

Bliss GVS Pharma Ltd Key Ratios

*All values are in Rs. Cr

Standalone

Consolidated

Particulars
Mar 2024
PBDIT Margin (%)23.18
PBIT Margin (%)19.29
PBT Margin (%)15.97
Net PROFIT Margin (%)8.36
Return On Networth / Equity (%)7.91
Return On Networth /Employed (%)11.19
Return On Assets (%)4.85
Total Debt / Equity (X)0.08
Asset Turnover Ratio (%)0.58

Bliss GVS Pharma Ltd Balance Sheet

*All values are in Rs. Cr

Standalone

Consolidated

Particulars
Mar 2024
Fixed Assets Annual329.95
Total Current Assets Annual772.98
Non Current Assets Annual379.57
Total Shareholders Funds Annual988.44
Total Assets Annual1,152.55

Bliss GVS Pharma Ltd Earning Calls

EPS (INR)

Expected

2.31

Reported

2.31

Surprise

0.00%

Jun 2024

EPS beaten by 0.00%

Mar 2024

EPS beaten by 0.00%

Dec 2023

EPS beaten by 0.00%

Get Your FAQs Right

As of Dec 5, 2024, Bliss GVS Pharma Ltd has a market capitalization of 1,179.34 Cr. Value Research classifies it as a Small-Cap company.
Yes, Bliss GVS Pharma Ltd is debt-free with a debt-to-equity ratio of 0.08.
In FY 2023 , Bliss GVS Pharma Ltd recorded a total revenue of approximately 605.46 Cr marking a significant milestone in the company's financial performance.
Bliss GVS Pharma Ltd's Future outlook anticipates robust growth, with forecasted earnings and revenue rising approximately 0.2% and -0.0% annually, respectively..
Bliss GVS Pharma Ltd's current PE ratio is 23.29.
Bliss GVS Pharma Ltd's ROCE averaged 12.4% from the FY ending March 2022 to 2024, with a median of 12.4%. It peaked at 13.9% in March 2022, reflecting strong capital efficiency over the period..
Bliss GVS Pharma Ltd's latest EBIT is Rs. 76.07 Cr, surpassing the average EBIT of Rs. 110.85 Cr over the 5 years..
Open Demat Account
Verify your phone
+91
*By signing up you agree to our terms & conditions